Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03852511
Title First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (FORTITUDE)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors PsiOxus Therapeutics Ltd
Indications

carcinoma

Therapies

NG-350A

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of California, Los Angeles (UCLA) Santa Monica California 90404 United States Details
University of Colorado Aurora Colorado 80045 United States Details
Memorial Sloan Kettering Cancer Center (MSKCC) New York New York 10038 United States Details
Cleveland Clinic Cleveland Ohio 44195 United States Details
The University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field